Arkolith/Insider Trading/RXRX/Form 4

Gibson Christopher

Chief Executive Officer, DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Dec 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$185K
Net Open-Market Flow
-$185K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 4, 2025Conversion(C)60K—$0974K
Dec 4, 2025Gift(G)20K—$0914K
Dec 4, 2025Sell(S)40K$4.63$185K934K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 4, 2025Conversion(C)60K—$04.8M

Transaction Codes

C
Conversion of a derivative
G
Gift
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001856369-25-000016) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML